TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned [Yahoo! Fin...
TRACON Pharmaceuticals, Inc. (TCON)
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
traconpharma.com
Company Research
Source: Yahoo! Finance
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the independent data monitoring committee (IDMC), following a review of ongoing safety and efficacy data on April 2, recommended the ENVASARC Phase 2 pivotal trial continue as planned. The ENVASARC Phase 2 pivotal trial completed enrollment in March 2024 with a total of 82 evaluable patients in cohort C of treatment with single agent envafolimab at 600 mg SQ every three weeks and final data are expected in the third quarter of 2024. The IDMC reviewed interim safety and efficacy data from 73 patients enrolled into cohort C who had the opportunity to complete two on-treatment scans (a minimum of 12 weeks of treatment). The objective response rate (ORR) is
Show less
Read more
Impact Snapshot
Event Time:
TCON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCON alerts
High impacting TRACON Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TCON
News
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- TRACON Pharmaceuticals Announces Reverse Stock SplitGlobeNewswire
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had its price target lowered by analysts at HC Wainwright from $6.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedGlobeNewswire
TCON
Earnings
- 3/5/24 - Beat
TCON
Sec Filings
- 4/12/24 - Form S-1
- 4/12/24 - Form 8-K
- 4/12/24 - Form 424B5
- TCON's page on the SEC website